Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALTITUDE NASH: A Phase 2, Randomized, Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With Nonalcoholic Steatohepatitis Stage 3 Fibrosis

Next Previous
Trial Profile

ALTITUDE NASH: A Phase 2, Randomized, Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With Nonalcoholic Steatohepatitis Stage 3 Fibrosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rencofilstat (Primary)
  • Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ALTITUDE; ALTITUDE-NASH
  • Sponsors Hepion Pharmaceuticals

Most Recent Events

  • 01 Mar 2025 Results assessing hepatic effects of rencofilstat treatment of MASH with advanced fibrosis, published in the Liver International.
  • 11 Jun 2024 Status changed from active, no longer recruiting to completed.
  • 14 Nov 2023 Results assessing hepatic functional improvement detected by hepquant duo within 120 days of treatment presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top